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AcrAB-TolC and their homologs are major multidrug efflux systems in Gram-negative
bacteria. The inner membrane component AcrB functions as a trimer. Replacement of
Pro223 by Gly in AcrB decreases the trimer stability and drastically reduces the drug efflux
activity. The goal of this study is to identify suppressor mutations that restore function
to mutant AcrBP223G and explore the mechanism of function recovery. Two methods
were used to introduce random mutations into the plasmid of AcrBP223G. Mutants
with elevated drug efflux activity were identified, purified, and characterized to examine
their expression level, trimer stability, interaction with AcrA, and substrate binding. Nine
single-site repressor mutations were identified, including T199M, D256N, A209V, G257V,
M662I, Q737L, D788K, P800S, and E810K. Except for M662I, all other mutations located in
the docking region of the periplasmic domain. While three mutations, T199M, A209V, and
D256N, significantly increased the trimer stability, none of them restored the trimer affinity
to the wild type level. M662, the only site of mutation that located in the porter domain,
was involved in substrate binding. Our results suggest that the function loss resulted from
compromised AcrB trimerization could be restored through various mechanisms involving
the compensation of trimer stability and substrate binding.
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INTRODUCTION
Escherichia coli multidrug transporter AcrB and its
homologues are the inner membrane component of the
Resistance-Nodulation-Division (RND) family transporters in
Gram-negative bacteria, which are major players in bacterial
multidrug resistance (Blair and Piddock, 2009; Nikaido and
Takatsuka, 2009; Nikaido and Pages, 2012; Zgurskaya and
Nikaido, 2012). AcrB forms a tripartite pump system with mem-
brane fusion protein (MFP) AcrA and outer membrane protein
TolC. In the AcrAB-TolC complex, AcrB determines substrate
specificity. The inward proton flow across the cytoplasmic mem-
brane through a proton-relay pathway in the transmembrane
domain of AcrB drives the active transport of substrates against
their concentration gradient. In the process of substrate efflux,
each AcrB monomer rotates through three conformations,
access (or loose), binding (or tight), and extrusion (or open)
(Murakami et al., 2006; Seeger et al., 2006, 2008; Vargiu and
Nikaido, 2012).
AcrB exists and functions as a homotrimer. Each subunit con-
sists of 12 transmembrane helices (TMH), and two large periplas-
mic loops (LPL) which form a periplasmic domain. Mutations in
Abbreviations: R6G, Rhodamine 6G; PMSF, phenylmethylsulfonyl fluoride;
WT, wild type; DDM, n-dodecylb-D-maltoside; NTA, nitrilotriacetic acid;
RND, resistance-nodulation-cell-division; SDS-PAGE, sodium dodecyl sulfate
polyacrylamide gel electrophoresis.
the transmembrane domain, including D407A, D408A, K940A,
and T978A, disrupt the proton relay network and disable the
pump (Su et al., 2006; Eicher et al., 2009; Pos, 2009). The two
LPLs exist in between TMH1 and TMH2 (LPL1) and TMH7 and
TMH8 (LPL2). The periplasmic domain is further divided into
a porter domain and a docking domain (Figure 1). Exchange
of AcrB and AcrD periplasmic loops altered the substrate pref-
erence of the proteins, suggesting that residues dictating sub-
strate specificity reside in the periplasmic domain (Elkins and
Nikaido, 2002). A deep binding pocket was later defined through
additional mutational and crystallographic studies (Yu et al.,
2005; Sennhauser et al., 2006; Nakashima et al., 2011; Eicher
et al., 2012). Depending on where they interact, substrates were
divided into two groups: groove binder and cave binder (Bohnert
et al., 2010; Takatsuka et al., 2010). Using Bodipy-FL-maleimide
labeling, Nikaido and coworkers elucidated the entire substrate
translocation pathway (Husain and Nikaido, 2010; Husain et al.,
2011). More recently a switching loop was found to separate the
binding location of different substrates into two sites, a proximal
pocket and a distal pocket (Vargiu and Nikaido, 2012; Kobayashi
et al., 2014). While large compounds bind to the proximal pocket
before moving toward the exit, smaller substrates bind to the
distal pocket.
Crystal structure of the entire AcrAB-TolC complex is not
yet available. Two models of interaction have been proposed
for AcrAB-TolC and similar tripartite transporters. A wrapping
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FIGURE 1 | Structure of AcrB (created using protein data bank file 1GIF
using Pymol). (A) Side view of a subunit from two different angles to reveal
the location of Pro223 (yellow) and the suppressor mutations (red). Pro223
and suppressor mutation sites were labeled. The locations of different
domains were marked. (B) Head view of AcrB trimer from the periplasmic
side.
model was proposed first, in which the top part of the AcrB
periplasmic domain interacts directly with the bottom of the
periplasmic domain of TolC and AcrA wraps around the AcrB-
TolC complex (Eswaran et al., 2004). Accordingly, the tip of the
AcrB periplasmic domain is sometimes referred to as the TolC
docking domain. More recently, a bridging model was proposed,
in which the hexametric MFP forms a cylindrical bridge to con-
nect the inner membrane protein and outer membrane protein
(Xu et al., 2012; Du et al., 2014). In this bridging model, the
outer membrane protein does not interact directly with the inner
membrane protein.
The proper function of this delicate drug efflux machine
requires the accurate assembly of the tripartite complex. While
extensive studies have been done on the understanding of sub-
strate binding, proton relay, and interaction between AcrB with
AcrA/TolC, much less emphasis have been focused on the inves-
tigation of the trimerization of AcrB and how trimerization
is correlated with other functional aspects such as interaction
with AcrA/TolC and substrate binding (Lu et al., 2014). In each
AcrB subunit, a long extended loop inserts into the neigh-
boring subunit, which is important to the formation of AcrB
trimer. We have previously created a well-folded monomeric
AcrB mutant through truncating 17 residues from the loop
(Lu et al., 2011). Later, we found that a single Pro223 to Gly
mutation is sufficient to disrupt trimerization and lead to a
drastic loss of activity (Yu et al., 2011). AcrBP223G has low
trimer affinity and its function can be partially restored through
stabilizing the trimer via the introduction of an inter-subunit
disulfide bond (Yu et al., 2011). To understand interactions
that stabilize AcrB trimer, we conducted random mutagene-
sis experiments to identify suppressor mutations that restore
functions to AcrBP223G. Nine single-site suppressor mutations
were identified. These suppressor mutants were purified and
characterized to investigate the potential mechanisms of function
restoration.
MATERIALS AND METHODS
RANDOMMUTAGENESIS OF AcrB AND MUTANTS SCREENING
Random mutagenesis of AcrB was achieved by two methods,
hydroxylamine hydrochloride treatment and error-prone PCR.
Chemical mutagenesis by hydroxylamine hydrochloride was per-
formed as described with slight modifications (Middlemiss and
Poole, 2004). Plasmid pQE70-acrBP223G was constructed in a pre-
vious study (Yu et al., 2011). pQE70-acrBP223G was incubated
in a potassium phosphate buffer (44mM, pH 6.0) containing
5mM EDTA and 0.46M hydroxylamine hydrochloride at 70◦C
for 40min. To quench the reaction, Tris-Cl (pH 8.0) and EDTA
were added to themixture to final concentrations of 90 and 9mM,
respectively. Treated plasmid was purified using a gel extraction
kit (Qiagen, CA) and used for transformation.
Error prone PCR was carried out using GeneMorph II
EZClone domain mutagenesis kit following the manufacturer’s
instruction (Agilent Technologies, Inc., Clara, CA). pQE70-
AcrBP223G was amplified using Mutazyme II DNA polymerase
with two pairs of primers. Primers PP1 (5′-atgcctaatttctttatcga
tcgc-3′) and PP2 (5′-AACGGCGTGGTG TCGTATGG-3′) were
used to introduce mutations into the first large periplasmic
loop of AcrB. Primers PP3 (5′-cgttgatcctgactccagctc-3′) and PP4
(5′- ATCGACCAGCTCTCGT ACAG-3′) were used to introduce
mutations in the second large periplasmic loop. PCR products
were separated and purified by gel electrophoresis. The purified
PCR product was used as mega-primers and pQE70-AcrBP223G
was used as the template during the following EZClone reaction.
DpnI was then added to digest the template plasmid.
Mutated plasmids generated through hydroxylamine
treatment or error-prone PCR were used to transform E. coli
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BW25113acrB through electroporation. The resultant cells
were incubated with 1mL LB broth with shaking at 37◦C for
1 h before plated on LB agar plates containing 100μg/mL ampi-
cillin, 50μg/mL kanamycin, and 16–32μg/mL AcrB substrate
erythromycin. Plasmids were extracted from colonies that were
able to grow on the erythromycin plates and retransformed into
BW25113acrB strain. Drug susceptibility was tested. Plasmids
that conferred decreased susceptibility were sequenced. Forty
two suppressor clones were sequenced. Each mutations identified
were further confirmed by introducing into P223G through site
directed mutagenesis. Mutations yield false positive results were
excluded. Nine unique single mutations that could restore P223G
activity were identified. T199M were identified 14 times, D256N
6 times, M662I 2 times, D788K 2 times, and each of the other five
mutations were only identified once. We have also observed the
G223P back-to wild type mutation twice.
DRUG SUSCEPTIBILITY ASSAY OF AcrB MUTANTS
AcrB activities were examined using a drug susceptibility assay.
The minimum inhibitory concentrations (MIC) of different
strains were measured as described (Takatsuka and Nikaido,
2009). Plasmids encoding different AcrB constructs were used
to transform BW25113acrB. Freshly transformed cells were
plated on LB-agarose plates containing 100μg/mL ampicillin and
50μg/mL kanamycin. The same ampicillin and kanamycin con-
centrations were used throughout the study. A single colony was
used to inoculate LB media supplemented with ampicillin and
kanamycin. The exponential-phase cultures of different strains
were diluted to an OD600nm unit of 0.1 using LB broth. 2μL of
this culture was spotted onto a series of LB-agar plate containing
the indicated concentration of AcrB substrates. The agar plates
were incubated at 37◦C overnight and the lowest concentration
of substrate that fully inhibited the bacteria growth was recorded
as the MIC. BW25113acrB strains transformed with plasmid-
encoded wild type AcrB or AcrBP223G were used as the positive
and negative controls, respectively. Each experiment was repeated
at least three times.
BLUE NATIVE PAGE ANALYSIS OF WILD TYPE AND MUTANT AcrB
Protein purification was conducted as described (Lu et al., 2011).
BN-PAGE analysis were performed as described (Wittig et al.,
2006). A phosphate buffer (20mM NaPi, 100mM NaCl, 0.03%
w/v DDM, pH 7.9) was used throughout the study unless oth-
erwise noted. Purified protein samples were mixed with blue
native loading buffer to reach a final concentration of 0.02M
6-aminoocaproic acid, 1% dodecylmaltoside, 5% glycerol, 0.1%
Coomassie brilliant blue G-250, pH 7.0. Protein samples were
loaded to a 4–15% polyacrylamide gradient gel. Electrophoresis
was performed using a running buffer (50mM Tricine, 7.5mM
imidazole, 0.02% Coomassie brilliant blue G-250, pH 7.0) at
15mA, in the 4◦C refrigerator for 2 h. Protein bands were visu-
alized after Coomassie blue stain. Band intensity was quantified
using the software ImageJ.
AcrA AND AcrB INTERACTION
pQE70-AcrB and its mutants were transformed into
BW25113acrB to study in vivo interaction between AcrB
and AcrA. Dithiobis succinimidyl propionate (DSP) crosslinking
and co-purification were performed as described with slight
modifications (Zgurskaya and Nikaido, 2000). Cells were cul-
tured overnight in 50mL LB supplemented with ampicillin and
kanamycin before harvested and washed with 5mL phosphate
buffer twice. The pellet was resuspended in 5mL phosphate
buffer containing 4mM DSP, and incubated at 37◦C for 30min.
Tris was added to a final concentration of 50mM to quench the
reaction. Proteins were purified using metal affinity chromatog-
raphy as described (Yu et al., 2011). After elution, dithiothreitol
(DTT) was added to the sample to a final concentration of
50mM to reduce the disulfide bond in the DSP linker. Finally, the
samples were subjected to SDS-PAGE and Western blot analyses
using anti-AcrA antibody.
FLUORESCENT LABELING
BODIPY-FL-maleimide labeling was conducted following pub-
lished method (Husain and Nikaido, 2010; Husain et al., 2011).
BW25113acrB cells harboring plasmids encoded AcrB mutants
were cultured overnight at 37◦C. Ten mL culture were harvested
by centrifugation at 4000 × g for 5min, washed twice using
10ml of buffer A (50mM potassium phosphate, 0.5mM MgCl2,
pH 7.0), and resuspended in 5mL of the same buffer containing
0.4% glucose and 6μMBODIPY-FL-maleimide. Themixture was
shaken at room temperature for 1 h. Next, Cells were harvested
by centrifugation, washed with 5mL buffer A supplemented
with 0.4% glucose, and then washed again with 5mL buffer A.
AcrB was then purified normally and resolved using SDS-PAGE.
Fluorescence images were collected using a Typhoon Phosphor
Imager with the excitation wavelength of 488 nm. The gel was
then stained with Coomassie blue stain and imaged under white
light. Band intensities were quantified using ImageJ (Rasband,
1997-2012; Schneider et al., 2012).
STRUCTURAL CHARACTERIZATION USING CIRCULAR DICHROISM (CD)
AND FLUORESCENCE SPECTROSCOPY
CD spectra of purified wild type AcrB and its mutants were col-
lected as described (Lu et al., 2011). CPM was from Invitrogen
(GRAND ISLAND, NY). The CPM reactivity experiment was
conducted as described in literature with minor modifications
(Alexandrov et al., 2008). Briefly, a DMSO solution of CPM was
freshly made at a concentration of 4.0 mg/mL. It was diluted in
phosphate buffer by 40-fold to make a work solution, which was
kept on ice during the experiment. 30μL of the CPM working
solution was mixed with 570μL phosphate buffer in which the
final concentration of protein was 4μM. The fluorescence signal
excited at 387 nm and emitted at 463 nm was monitored upon
heating. Fluorescence emission intensity was normalized against
the maximum intensity. Each experiment was performed at least
three times.
RESULTS
IDENTIFICATION OF SINGLE POINT SUPPRESSOR MUTATIONS THAT
RESTORE ACTIVITY TO AcrBP223G
In a previous study we found that mutation of P223 into Gly
reduced the activity of AcrB to a level close to that of the acrB
knockout strain (Yu et al., 2011). P223 locates close to the tip
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of a long protruding loop critical for AcrB trimerization. The
mutation had little effect on proteins structure except that puri-
fied AcrBP223G migrated mainly as a monomer in BN-PAGE. In
addition, the observed function loss could be partially restored
by the introduction of a pair of strategically placed Cys residues
and the formation of inter-subunit disulfide bond, indicating
that the disruption of trimerization was a major cause of func-
tion loss in AcrBP223G (Yu et al., 2011). In this study, random
mutagenesis was conducted to identify suppressor mutations that
restore function to AcrBP223G. Plasmid encoding AcrBP223G was
first subjected to randommutagenesis, and then transformed into
BW25113acrB and plated onto LB agar plate containing 16 or
32μg/mL erythromycin. Erythromycin is a well-established AcrB
substrate. Here we chose to use erythromycin mainly due to the
large difference of MIC between BW25113acrB containing WT
AcrB (128μg/mL) and AcrBP223G (8μg/mL).
Two methods were used to introduce random mutations into
AcrBP223G, hydroxylamine hydrochloride treatment and error
prone PCR. The hydroxylamine hydrochloride method is biased,
as it only results in transition from C to T and G to A (Middlemiss
and Poole, 2004). Two suppressor mutations, T199M and D256N,
were recovered using this method. The error-prone PCR method
generated a more uniform spectrum of mutations with equiva-
lent mutation rates. Two pairs of primers, PP1/PP2 and PP3/PP4
were used to introduce random mutations into two periplas-
mic regions: between residues 30–332 and residues 494–889. We
focused our search in the two long loops that form the periplasmic
domain. With this method, we rediscovered T199M and D256N,
and seven additional single point suppressor mutations including
A209V, G257V, M662I, Q737L, D788K, P800S, and E810K.
To confirm that the decreased drug susceptibility was actually
caused by the restoration of AcrB activity, we introduced
these suppressor mutations through site directed mutage-
nesis into plasmid pQE70-AcrBP223G and transformed the
resultant plasmids into BW25113acrB for activity assay.
Drug susceptibilities were measured for four AcrB sub-
strates, including erythromycin, novobiocin, tetracycline, and
tetraphenylphosphonium. BW25113acrB transformed with
pQE70-AcrB, pQE70-AcrBP223G, or the empty plasmid pQE70
were used as controls. MICs of the mutants and controls were
shown in Table 1. For all AcrB substrates tested, the addi-
tional suppressor mutation greatly enhanced the activity of
AcrBP223G.
A closer inspection reveals that there were several differ-
ent MIC patterns for the nine suppressor mutants: (a) T199M,
G257V, Q737L, D788K, and E810K restored the MIC to all four
tested antibiotics to comparable levels. (b) For A209V, M662I,
and P800S, the MICs to erythromycin were almost fully recov-
ered (8-folds), but only limited effects were observed (2-folds)
for the other three antibiotics. (c) For D256N, the MIC to ery-
thromycin was only partially recovered (4-folds), but for other
three antibiotics the recovery effect was quite obvious. To under-
stand the mechanism of function restoration, we mapped the
suppressor mutations (red) as well as P223 (yellow) onto the
crystal structure of AcrB (Figure 1). Eight out of the nine repres-
sor mutations located in the top part (docking domain) of the
periplasmic domain. The only exception is M662, which is in the
middle of the periplasmic domain (porter domain). Thus, eight
out of nine suppressor mutations (other than M662I) are located
distant from the substrate translocation pathway, and thus are
not likely to be directly involved in interaction with substrates.
These mutations might have led to subtle changes of the sub-
strate translocation pathway through certain allosteric effect and
subsequently resulted in the observed difference.
SEQUENCE ALIGNMENT OF SUPPRESSOR MUTATIONS
To probe the potential role of these suppressor mutations, we
aligned the E. coli AcrB sequence with 13 homologues. Table 2
showed the residues occupying these locations in all sequences
together with their consensus score (Waterhouse et al., 2009).
Substitutions identified in the suppressor mutation were also
included. Although overall the sequence of AcrB is highly con-
served among Gram-negative bacteria, most suppressor mutation
sites were poorly conserved as revealed by the low consensus
scores. This is a reasonable observation since mutation of highly
conserved sites by itself might cause function loss as they are likely
to play important roles in structure and function.
EFFECT OF SUPPRESSOR MUTATION ON PROTEIN EXPRESSION
To determine the effects of additional mutations on AcrBP223G,
we first examined the expression level of these double
mutants. Plasmid encoding each mutant was transformed into
BW25113acrB for protein expression under the basal condition.
Membrane vesicles were then extracted from the same amount
of cells and subjected to Western blot analysis using an anti-
AcrB antibody. We have previous demonstrated that AcrBP223G
expressed at a similar level as the wild type AcrB (Yu et al.,
2011). Here we found that all mutant except for AcrBP223G/D256N
expressed at levels similar to that of the wild type AcrB and
AcrBP223G (Figure S1). The expression level of AcrBP223G/D256N
was approximately three folds higher than AcrBP223G. The exact
reason for the observed increase of expression level is not clear.
Table 1 | MIC (µg/mL) of BW25113acrB harboring the indicated
plasmids.
Plasmids MIC (µg/mL)
Ery Nov Tet TPP
pQE70-AcrB 128 320 2.56 640
pQE70-AcrBP223G 8 40 0.64 20
pQE70-AcrBP223G/T199M 128 160 2.56 640
pQE70-AcrBP223G/A209V 64 80 1.28 40
pQE70-AcrBP223G/D256N 32 160 2.56 320
pQE70-AcrBP223G/G257V 64 160 2.56 160
pQE70-AcrBP223G/M662I 128 80 1.28 160
pQE70-AcrBP223G/Q737L 64 160 2.56 160
pQE70-AcrBP223G/D788K 128 160 2.56 320
pQE70-AcrBP223G/P800S 64 80 1.28 80
pQE70-AcrBP223G/E810K 128 160 2.56 320
Drugs tested were Ery, erythromycin; Nov, novobiocin; TPP,
tetraphenylphosphonium; and Tet, tetracycline.
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Table 2 | Sequence alignment of AcrB with homologes at sites that restored AcrBP223G activity.
Residue number 199 209 256 257 662 737 788 800 810
AcrB(E. coli) T A D G M Q D P E
Replaced by M V N V I L K S K
AcrD (E. coli) T S D G V L Y S G
AcrF (E. coli) T V D G V A L F Y
MexB (P. aeruginosa) T A D G M A W F Y
AcrB(H. pylori) D V I G V Q E R P
AcrB(Y. pestis) T I D G V A W F Y
AcrB(V. cholera) V S G D Q I W Q E
AcrB(K. pneumonia) T A D G V A W F Y
AdeB (A. baumannii) L R T N P D G Q R
AmeB (A. tumefaciens) T Q G A I D N S S
TtgB (P. Putita) T A D G V L Y S G
CmeB (C. coli) G V N E G M N T V
AmrB (P. aeruginosa) A H G G N M E K I
MtrD (N. meningitidis) A N S N V G V T T
Consensus score 3 2 3 4 4 3 2 2 0
Replacement residues identified in suppressor mutants were also shown.
EFFECT OF SUPPRESSOR MUTATION ON TRIMER STABILITY
BN-PAGE was used to compare the trimer stability of each
mutant. We have previously shown that while freshly purified
wild type AcrB migrates predominantly as trimers, AcrBP223G
migrates predominantly as monomers (Yu et al., 2011). Figure 2A
showed the representative gel images of the BN-PAGE results of
the repressor mutants. AcrBP223G and wild type AcrB were also
shown as controls. Protein band intensities in the gel were quan-
tified using ImageJ and trimer to monomer ratios were shown
in Figure 2B. Two observations could be made: first, the trimer
stability of all repressor mutants were much lower than that
of the wild type AcrB; second, among the 9 suppressors, only
three showed a significant increase of trimer stability, including
AcrBT199M/P223G, AcrBA209V/P223G, and AcrBD256N/P223G. Other
six mutations caused decreases in trimer stability as compared to
AcrBP223G, especially in the case of AcrBQ737L/P223G. This result
was a surprise since we expected the suppressor mutations to
recover the MIC of AcrBP223G through increasing the trimer
stability.
INTERACTION WITH AcrA
The majority of mutations occurred at the top of the periplasmic
domain in AcrB, the interaction site of AcrB with AcrA and/or
TolC. A crosslinking protocol has been previously developed by
Tikhonova et al. to demonstrate that AcrA and AcrB make direct
contact (Zgurskaya andNikaido, 2000; Tikhonova and Zgurskaya,
2004). To verify if these mutations have any impact on AcrA-AcrB
interaction, we treated BW25113acrB cells expressing different
AcrB constructs with chemical crosslinker DSP, purified pro-
teins using metal affinity chromatography, cleaved the disulfide
bond in the crosslinker, and examined the quantity of AcrA co-
purified with AcrB. The level of AcrA co-purified was revealed
through anti-AcrA Western blot analysis, while the amount of
purified AcrB was examined through staining a duplicate gel with
Coomassie blue stain. Representative gel images were showed in
Figure 3. BW25113acrB transformed with pQE70 vector were
used as a negative control to confirm that the signal was not from
non-specific interaction of AcrA with the Ni-nitrilotriacetic acid
(NTA) resin. Little signal could be detected for the negative con-
trol, suggesting AcrA did not retain on Ni-NTA resin without
being cross-linked with AcrB.
The relative amounts of AcrA crosslinked to AcrBP223G and
wild type AcrB were similar, indicating that the P223G mutation,
while decreased the trimer stability and compromised drug efflux
activity, could still bind effectively to AcrA. The relative levels of
AcrA cross-linked with all suppressor mutants tested were not
significantly different from that of wild type AcrB or AcrBP223G.
These results suggest that interaction with AcrA was not affected
by the initial P223G mutation. Therefore, function restoration in
the suppressor mutants was not likely through strengthening the
interaction with AcrA.
M662 IS ON THE SUBSTRATE TRANSLOCATION PATHWAY
Of all suppressor mutants, AcrBP223G/M662I is especially interest-
ing. M662I is the only mutation that occurred in the AcrB porter
domain. Nikaido and coworkers have developed a BODIPY-FL-
maleimide labeling method to probe the substrate translocation
pathway in AcrB periplasmic domain and proved that Phe664 and
Phe666 were involved in substrate binding (Husain and Nikaido,
2010; Husain et al., 2011). In this method, a Cys was introduced
at a target location. BODIPY-FL-maleimide selectively reacts with
Cys introduced along the substrate translocation pathway. We
speculate that Met662 was involved in substrate binding based
on its location in the AcrB structure. To test the hypothesis, we
conducted Bodipy-FL-maleimide labeling of a Cys introduced
to replace M662 (Figure 4). Although there are two intrinsic
cysteines in AcrB, both of them are distant from the transloca-
tion pathway. Thus, they were used as the negative control to
confirm that BODIPY-FL-maleimide specifically label Cys at the
substrate binding site. For positive control, we used AcrBF664C,
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FIGURE 2 | Quarternary structure analysis. (A) Representative images of BN-PAGE analyses of wild type (WT) and mutant AcrB. (B) Trimer to monomer ratio
for each mutant was derived from the BN-PAGE analysis. Experiments were repeated three times. The average value and standard deviation were shown.
a previously confirmed substrate-binding residue (Husain and
Nikaido, 2010). As expected, no labeling was observed in wild
type AcrB while AcrBF664C was labeled well. AcrBM662C could
also be labeled by BODIPY-FL-maleimide, suggesting Met662
was indeed involved in substrate binding, most likely at the
entrance of the drug translocation pathway. The relative level
of labeling was weaker in AcrBM662C as compared to AcrBF664C,
suggesting that substrate interaction at this site was not as
strong.
M662I MUTATION IMPROVES SUBSTRATE BINDING IN THE DEEP
BINDING POCKET OF AcrBP223G
To investigate the potential effect of M662I mutation on substrate
accessibility to the translocation pathway, we investigated the
level of labeling of a previously verified site in the deep bind-
ing pocket, D276C (Husain and Nikaido, 2010; Lu et al., 2014).
We performed BODIPY-FL-maleimide labeling in AcrBD276C,
AcrBP223G/D276C and AcrBP223G/D276C/M662I (Figure 4B). The
level of labeling was normalized to the labeling level in AcrBD276C.
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In AcrBP223G/D276C, the level of labeling was approximately
14 ± 4% of the level of labeling in AcrBD276C. The sup-
pressor mutation, AcrBP223G/D276C/M662I, improved the label-
ing level to 28 ± 5%, approximately twice of the level in
AcrBP223G/D276C. This result is consistent with the observed
partial recovery of drug efflux activity in the repressor
mutant.
FIGURE 3 | Interaction with AcrA. Anti-AcrA Western blot analysis (top
panel) of co-purified AcrA from BW25113acrB expressing wild type or
mutant AcrB. The empty vector pQE70 was used as the negative control.
The same gel was stained using Coomassie blue stain (bottom) to reveal
that similar amount of AcrB was present in each sample.
M662I MUTATION DID NOT AFFECT THE OVERALL STRUCTURE NOR
IMPROVE THE STABILITY OF AcrBP223G
To further elucidate the mechanism of function restoration, we
compared the structure and stability of AcrBP223G/M662I with
those of AcrBP223G. CD spectra of both mutants overlap well
on top of the spectrum of wild type AcrB, indicating that the
overall conformation was not affected by P223G, nor the addi-
tional M662I mutations (Figure 5A). Next, we examined the
stability of the proteins. In a previous study, we measured the
thermal denaturation profiles of wild type AcrB and AcrBP223G
using a thermal denaturation method monitoring the CD sig-
nal at 222 nm (Yu et al., 2011). No significant difference was
observed, indicating that either the two proteins have similar
stability, or the technique is not sensitive to the intended mea-
surement. Here we compared the stability of the proteins using a
fluorescence labelingmethod (Alexandrov et al., 2008). Unfolding
was monitored via the exposure of Cys residues upon heating and
the subsequent reaction with N-[4-(7-diethylamino-4-methyl-3-
coumarinyl) phenyl] maleimide (CPM). CPM is a thiol specific
probe whose fluorescence emission intensity increased drasti-
cally upon reaction with a sulfhydryl group in a protein. The
formation of a thioether and the concurrent attachment to the
protein is revealed by a surge of fluorescence emission at 463 nm
(excited at 387 nm). Since free Cys residues are usually found in
the hydrophobic core of a folded protein structure, the unfolding
of the protein exposes the Cys and greatly accelerates the thiol-
specific reaction. The thermal denaturation of wild type AcrB
revealed a fluorescence surge as approximately 52◦C (Figure 5).
The transition temperatures of the two mutants were similar as
the transition temperature of the wild type protein, while the
slopes were less steep, indicating a less cooperative unfolding
behavior. This difference could be due to a decrease of trimer
stability, as the thermal denaturation experiment monitors the
global unfolding of the protein including trimer dissociation and
FIGURE 4 | Bodipy-FL-maleimide (FL) labeling of residues on the
substrate translocation pathway. (A) Labeling of WT AcrB, AcrBM662C,
and AcrBF664C. The same gel was stained using Coomassie blue stain
(CB). The two bands in the molecular weight marker are 120 kDa (top)
and 85 kDa (bottom). (B) Labeling of AcrBD276C, AcrBP223G/D276C, and
AcrBP223G/D276C/M662I. The same gel was stained using Coomassie blue
stain (CB). The level of labeling in AcrBP223G/D276C and
AcrBP223G/D276C/M662I was normalized to the level of labeling in
AcrBD276C. The average value and standard deviation of three
independent experiments were shown.
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FIGURE 5 | Structural and stability characterization of AcrBP223G and
AcrBP223G/M662I. (A) CD spectra of AcrBP223G (black dotted) and
AcrBP223G/M662I (gray continuous) overlap with the spectrum of WT AcrB
(black continuous). No observable change was induced by the mutations.
(B) Thermal denaturation of WT (black diamonds), AcrBP223G (open squares),
and AcrBP223G/M662I (gray squares) monitored using the reactivity with CPM
(right panel). Fluorescence intensity was normalized to the maximum
reading. Shown are the average values of three measurements. The average
value and standard deviation for WT AcrB was shown as an example to reveal
the reproducibility of the method (left panel).
protomer unfolding. The unfolding profiles of AcrBP223G and
AcrBP223G/M662I were very similar, indicating that the restoration
of function was not a result of improving structural stability.
DISCUSSION
Several factors are critical for the proper function for AcrB: drug
binding, interaction with AcrA and TolC, proton relay through
the transmembrane domain, and AcrB trimerization. In this
study, we identified nine single suppressor mutations that could
restore function to AcrBP223G. Trimer affinity of purified mutants
was examined using BN-PAGE. Three mutants had higher trimer
stability than AcrBP223G, while remained drastically lower than
that of the wild type AcrB. For the rest of the mutant, trimer
stability was not improved. They are likely to restore functions
through alternative mechanisms. However, it is possible that
in vivo in bacterial cells these mutations could enhance trimer sta-
bility as a secondary effect of other interactions, such as binding
with AcrA/TolC or substrate.
The next factor we tested was the interaction with partner pro-
teins.We chose to investigate the interaction with AcrA since AcrA
and AcrB make direct contact according to both the wrapping
model and bridging model, while TolC does not interact directly
with AcrB in the bridging model. We found that AcrBP223G and
all suppressor mutants could be crosslinked with similar amount
of AcrA as wild type AcrB, suggesting that the loss of func-
tion in AcrBP223G was not likely an effect on disruption of AcrA
interaction and the restoration of function was not an effect of
improving interaction with AcrA.
Finally we focused on the study of one suppressor mutant,
M662I, which is at the porter domain and close to the substrate
translocation pathway. Using a fluorescent labeling experiment,
we found that M662 was involved in substrate binding. Substrate
binding in AcrB involves mainly hydrophobic interactions. Ile is
slightly more hydrophobic than Met according to hydrophobic-
ity scales generated by different studies (Rose et al., 1985; White
and Wimley, 1999). It is interesting to notice that such a small
change of hydrophobicity could significantly increase theMIC for
all substrates tested. We further measured the level of labeling of
residue in the deep binding pocket, D276C. We found that the
M662I mutation doubled the relative level of labeling at this site
on the P223G background. Finally, we confirmed that the addi-
tional M662I mutation did not induce an observable change on
AcrBP223G structure and stability.
While ligand-induced oligomerization has been observed in
many receptor and signaling proteins, the ligand binding sites in
these cases usually locate at the inter-subunit interface (Sigalov,
2010; Atanasova and Whitty, 2012). In AcrB, the substrate
translocation pathway, including M662, is distant from the inter-
subunit interface. Therefore, the potential effect on AcrB trimer
stability, if any, has to be allosteric. Interaction between neigh-
boring subunits in an AcrB trimer is clearly critical for function.
During drug efflux each subunit adopts a different conforma-
tion and cycles through the three conformations in turn. Recently
Pos and co-workers determined the structure of AcrB at high
enough resolution to resolve unambiguously the side chains of
critical residues involved in proton translocation in the trans-
membrane domain and rationalized how the cross-talk among
protomers across the trimerization interface might lead to a more
kinetically efficient efflux system (Eicher et al., 2014). Therefore,
each subunit has to be able to “sense” the state of its neighbors
and undergoes conformational change in a concerted manner.
A key element differentiates the various conformational states is
the mode of interaction with the substrate. Therefore, it is possi-
ble that improved interaction with substrate could enhance efflux
activity either directly through more efficient uptake or indi-
rectly via increasing trimer affinity. Interestingly, some ligands are
found to enhance the transport of other ligands by AcrB, suggest-
ing that ligand binding could potentially play a more active role
in efflux (Kinana et al., 2013).
For the rest of the repressor mutant, it remains unclear
how these mutations restored the function loss in AcrBP223G.
Middlemiss and Poole conducted a random mutagenesis study to
identify residues that are critical to the function of MexB, a close
homolog of AcrB (Middlemiss and Poole, 2004). Most mutations
that affected function were mapped to regions of MexB predicted
to be involved in trimerization or interaction with MexA. In the
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same study, five suppressor mutations were identified to restore
the activity of the MexBG220S, which was proposed to cause
function loss via disruption of trimerization. Interestingly, sim-
ilar as our observation in this study that all suppressor mutants
identified, E796K, V203M/G581D, A737V, L738F, and D793N,
locate in the docking area of the periplasmic domain. Protein-
protein interaction during the assembly of the functional pump,
including the intra-species interaction (trimerization of AcrB or
MexB) and inter-species interaction with partner proteins (AcrA
and/or TolC, MexA and/or OprM), seem to be correlated. The
inter-species interaction may, to some degree, strengthen the
intra-species interaction and compensate for function loss as a
result of compromised trimerization. Finally, we have to acknowl-
edge the limitation of the method we used to probe protein trimer
stability using purified protein samples. It is possible that the sup-
pressor mutations might have a more drastic effect on improving
trimer stability in the cell membrane, and thus compensating for
the loss of activity by directly improving the interaction between
neighboring substrates in a trimer.
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